玻璃体内注射贝伐单抗后的眼内炎：巴基斯坦三级医疗中心的发病率、管理及视力转归
Endophthalmitis Postintravitreal Bevacizumab Injections: Incidence, Management, and Visual Outcome in Tertiary Care Center in Pakistan.
作者信息
Rizwan Amna, Asghar Asfandyar, Sughra Ume, Yasmin Naila
机构信息
Department of Ophthalmology, KEMU, Lahore, Pakistan.
Department of Ophthalmology, Fauji Foundation Hospital, Rawalpindi, Pakistan.
出版信息
Oman J Ophthalmol. 2022 Mar 2;15(1):20-24. doi: 10.4103/ojo.ojo_103_21. eCollection 2022 Jan-Apr.
PURPOSE
The purpose is to study the incidence, characteristics, management, and visual outcome of endophthalmitis postintravitreal bevacizumab (Avastin®) injections.
METHODS
Retrospective cohort study conducted at Fauji Foundation Hospital that is a tertiary care center in Rawalpindi, Pakistan. The study duration was from January 1, 2015 to March 31, 2020. A total of 2321 eyes of 1407 patients were treated with Intravitreal bevacizumab (IVB) in a minor operation theater using standard aseptic measures. We studied the incidence, clinical characteristics, treatment, and visual outcomes of endophthalmitis post-IVB.
RESULTS
Seven eyes (0.30%) out of 2321 eyes developed post-IVB endophthalmitis during the study period. Three eyes (42.8%) were culture positive and four eyes (57.2%) were culture negative. Five eyes (71.4%) showed visual improvement and two eyes (28.6%) did not show visual improvement.
CONCLUSION
Prompt intravitreal antibiotic along with vitreous tap in cases of postintravitreal endophthalmitis may prevent vision loss which provides a useful alternative to immediate pars plana vitrectomy that requires more expertise, equipment, and an operation theater.
目的
研究玻璃体内注射贝伐单抗（阿瓦斯汀®）后眼内炎的发生率、特征、处理方法及视力预后。
方法
在巴基斯坦拉瓦尔品第的三级医疗中心法吉基金会医院进行回顾性队列研究。研究时间为2015年1月1日至2020年3月31日。共有1407例患者的2321只眼在小型手术室采用标准无菌措施接受了玻璃体内贝伐单抗（IVB）治疗。我们研究了IVB后眼内炎的发生率、临床特征、治疗方法及视力预后。
结果
在研究期间，2321只眼中有7只眼（0.30%）发生了IVB后眼内炎。3只眼（42.8%）培养阳性，4只眼（57.2%）培养阴性。5只眼（71.4%）视力改善，2只眼（28.6%）视力未改善。
结论
对于玻璃体内注射后眼内炎病例，及时进行玻璃体内注射抗生素并抽取玻璃体，可能预防视力丧失，这为立即进行需要更多专业知识、设备和手术室的玻璃体切割术提供了一种有用的替代方法。
Zotero 插件